Last reviewed · How we verify
Placebo (10 mg)
Placebo produces therapeutic effects through patient expectation and the psychobiological placebo response, rather than through a pharmacologically active ingredient.
Placebo produces therapeutic effects through patient expectation and the psychobiological placebo response, rather than through a pharmacologically active ingredient. Used for Clinical trial control comparator (non-therapeutic use).
At a glance
| Generic name | Placebo (10 mg) |
|---|---|
| Sponsor | Bayer |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance that lacks direct pharmacological activity. Its therapeutic effects arise from the patient's expectation of benefit, conditioning, and activation of endogenous healing mechanisms including neurobiological pathways. Placebo responses are well-documented across multiple therapeutic areas and serve as the control comparator in randomized clinical trials.
Approved indications
- Clinical trial control comparator (non-therapeutic use)
Common side effects
- Nocebo effects (adverse events attributed to placebo expectation)
Key clinical trials
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (PHASE2)
- Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers (PHASE1)
- Adenosine 2A Receptor Antagonism and AIH in ALS (PHASE1, PHASE2)
- Toddler Biomarker of Nutrition Study (NA)
- A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) (PHASE3)
- Effect of L. Reuteri LM1063 on Sleep Health Improvement (NA)
- A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn) (PHASE3)
- A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (10 mg) CI brief — competitive landscape report
- Placebo (10 mg) updates RSS · CI watch RSS
- Bayer portfolio CI